Anticonvulsant Pharmacology

Seizure Management & Antiepileptic Drugs

Mechanisms, clinical applications, adverse effects, and high-yield prescribing principles for USMLE Step 1.

Seizure Pathophysiology

  • Seizure = paroxysmal, hypersynchronous electrical discharge in cerebral cortex
  • Cellular hallmarks
    • Prolonged neuronal depolarization
    • Sustained high-frequency repetitive firing (SHFRF)
    • Followed by prolonged post-ictal hyperpolarization
  • Imbalance between excitation (glutamate) and inhibition (GABA)
    • Excess glutamate → NMDA/AMPA receptor overactivation
    • Reduced GABAA-mediated Cl⁻ influx → diminished inhibition
  • Ion channel dysfunction
    • Voltage-gated Na⁺ channels: sustained opening → repetitive firing
    • T-type Ca²⁺ channels: burst firing in thalamocortical circuits (absence seizures)
    • K⁺ channel defects impair repolarization
  • Therapeutic goal = restore normal electrical rhythm without suppressing physiological neural activity.

🔬 Anticonvulsant Mechanisms

Na⁺ Channel Blockade

  • Bind to inactivated state of fast voltage-gated Na⁺ channels
  • Increase refractory period → reduce sustained repetitive firing
  • Representative drugs
    • Phenytoin
    • Carbamazepine
    • Lamotrigine
    • Topiramate (also blocks AMPA)

GABA Potentiation

  • Enhance GABAA-mediated Cl⁻ influx → hyperpolarization
  • Barbiturates: prolong Cl⁻ channel opening
  • Benzodiazepines: increase frequency of Cl⁻ channel opening
  • Valproic acid: inhibits GABA transaminase (↑ GABA levels)

Glutamate Receptor Blockade

  • Reduce excitatory neurotransmission
  • AMPA receptor blockade
    • Topiramate
    • Lamotrigine
  • NMDA receptor blockade
    • Felbamate

T‑Type Ca²⁺ Channel Blockade

  • Block low-threshold (T-type) Ca²⁺ channels in thalamic neurons
  • Suppresses thalamocortical burst firing → absence seizures
  • Representative drugs
    • Ethosuximide (selective)
    • Valproic acid (also blocks)
Na⁺ block ↓ firing + GABA ↑ ↓ excitability seizure suppression

📋 Seizure Types & First‑Line Agents

Seizure TypePreferred AgentsKey Notes
Focal (partial) – simple or complex Valproic acid · Phenytoin · Carbamazepine · Lamotrigine Lamotrigine often better tolerated long‑term
Generalized tonic‑clonic Valproic acid · Phenytoin · Carbamazepine · Lamotrigine Carbamazepine may exacerbate absence/myoclonic
Absence (petit mal) Ethosuximide · Valproic acid Ethosuximide is highly selective for absence
Status epilepticus IV Lorazepam · IV Diazepam · IV Phenytoin · IV Fosphenytoin Fosphenytoin is water‑soluble, faster infusion
  • Do not use carbamazepine or phenytoin for absence seizures — they are ineffective and may worsen.

💊 Primary Anticonvulsants

Phenytoin

  • Mechanism: blocks inactivated Na⁺ channels → prevents seizure propagation
  • Uses: focal, tonic‑clonic, status epilepticus
  • PK:
    • Variable oral absorption
    • Nonlinear (zero‑order) elimination at therapeutic doses
    • Induces CYP450 (auto‑induction not prominent)
    • Highly protein‑bound (albumin)
  • Adverse effects:
    • CNS depression (nystagmus, ataxia, sedation)
    • Gingival hyperplasia
    • Hirsutism
    • Osteomalacia (↓ vitamin D metabolism)
    • Megaloblastic anemia (↓ folate absorption)
    • Aplastic anemia — monitor CBC
    • Teratogenicity: cleft lip/palate, fetal hydantoin syndrome

Carbamazepine

  • Mechanism: identical to phenytoin (Na⁺ channel blockade)
  • Uses:
    • Focal and tonic‑clonic seizures
    • DOC for trigeminal neuralgia
    • Bipolar disorder (mood stabilization)
  • PK: potent CYP450 inducer (including its own metabolism → auto‑induction)
  • Adverse effects:
    • CNS depression (diplopia, dizziness, sedation)
    • Osteomalacia
    • Megaloblastic anemia
    • Aplastic anemia / agranulocytosis
    • Exfoliative dermatitis (Stevens‑Johnson risk)
    • SIADH → dilutional hyponatremia
    • Teratogenicity: cleft lip/palate, spina bifida

Valproic Acid

  • Mechanism: Na⁺ blockade + GABA transaminase inhibition + T‑type Ca²⁺ blockade
  • Uses:
    • Broad-spectrum: focal, tonic‑clonic, absence
    • Bipolar mania
    • Migraine prophylaxis
  • PK: inhibits CYP450 (↑ levels of other drugs)
  • Adverse effects:
    • Hepatotoxicity (toxic metabolite – risk highest in young children)
    • Thrombocytopenia
    • Pancreatitis
    • Alopecia (reversible)
    • Weight gain
    • Teratogenicity: spina bifida (neural tube defect)

Ethosuximide

  • Mechanism: selective T‑type Ca²⁺ channel blockade in thalamus
  • Use: absence seizures only
  • Adverse effects: GI upset, drowsiness, headache; rarely aplastic anemia
  • Valproic acid is the broadest-spectrum AED, but its hepatotoxicity and teratogenicity limit use in some populations.

🧪 Other Anticonvulsants

Lamotrigine

  • Na⁺ channel blockade + glutamate (AMPA) receptor inhibition
  • Uses: focal, tonic‑clonic, Lennox‑Gastaut, bipolar maintenance
  • Slow titration required to reduce rash risk
  • Adverse effect: Stevens‑Johnson syndrome (rash, fever, mucosal involvement)

Topiramate

  • Na⁺ channel blockade + AMPA blockade + GABA enhancement
  • Uses: focal seizures (adults & children >2 yr), migraine prophylaxis
  • Adverse effects: weight loss, cognitive slowing, paresthesias, metabolic acidosis, nephrolithiasis

Felbamate

  • Na⁺ channel blockade + NMDA receptor blockade
  • Use: refractory seizures (often adjunctive)
  • Serious adverse effects: aplastic anemia, hepatotoxicity — reserved for refractory cases

Gabapentin

  • Binds α₂δ subunit of voltage‑gated Ca²⁺ channels → ↓ neurotransmitter release
  • May enhance GABAergic effects (indirect)
  • Uses: focal seizures (adjunct), neuropathic pain (postherpetic neuralgia)
  • Renally excreted; no hepatic metabolism
  • Adverse effects: sedation, dizziness, peripheral edema

🧠 Clinical Pearls & Drug Interactions

  • Additive CNS depression: all AEDs potentiate other CNS depressants (ethanol, benzodiazepines, opioids)
  • Abrupt withdrawal: may precipitate rebound seizures or status epilepticus — taper slowly
  • Oral contraceptive efficacy: reduced by CYP450‑inducing AEDs (phenytoin, carbamazepine, topiramate, felbamate)
    • Use alternative or high‑dose OCP / backup contraception
  • Pregnancy: all AEDs carry teratogenic risk
    • Valproate: highest risk (neural tube defects, cognitive impairment)
    • Folate supplementation (4–5 mg/day) recommended preconception
  • Monitoring:
    • CBC, LFTs, serum levels (for phenytoin, carbamazepine, valproate)
    • Bone density (vitamin D / calcium) with long‑term enzyme inducers
  • Phenytoin has zero‑order kinetics at therapeutic doses — small dose increments cause disproportionate level increases and toxicity.
  • For status epilepticus: IV lorazepam is first‑line; fosphenytoin is preferred over phenytoin due to better water solubility and faster infusion.

Enzyme Induction vs. Inhibition

DrugCYP450 EffectClinical Consequence
PhenytoinInducer↓ warfarin, OCP, corticosteroids
CarbamazepineInducer (auto‑induction)↑ own clearance; ↓ OCP, warfarin
Valproic acidInhibitor↑ lamotrigine, phenytoin, phenobarbital levels
TopiramateInducer (mild)↓ OCP efficacy
FelbamateInducer & inhibitorComplex interactions; monitor levels